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http://www.biomedcentral.com/1471-2342/14/11RESEARCH ARTICLE Open AccessAnimal study assessing safety of an acoustic
coupling fluid that holds the potential to avoid
surgically induced artifacts in 3D ultrasound
guided operations
Asgeir S Jakola1,2,3,4*, Arve Jørgensen5, Tormod Selbekk4,6, Ralf-Peter Michler7, Ole Solheim1,4, Sverre H Torp8,9,
Lisa M Sagberg4, Petter Aadahl5 and Geirmund Unsgård1,4Abstract
Background: Use of ultrasound in brain tumor surgery is common. The difference in attenuation between brain
and isotonic saline may cause artifacts that degrade the ultrasound images, potentially affecting resection grades
and safety. Our research group has developed an acoustic coupling fluid that attenuates ultrasound energy like the
normal brain. We aimed to test in animals if the newly developed acoustic coupling fluid may have harmful effects.
Methods: Eight rats were included for intraparenchymal injection into the brain, and if no adverse reactions were
detected, 6 pigs were to be included with injection of the coupling fluid into the subarachnoid space. Animal
behavior, EEG registrations, histopathology and immunohistochemistry were used in assessment.
Results: In total, 14 animals were included, 8 rats and 6 pigs. We did not detect any clinical adverse effects, seizure
activity on EEG or histopathological signs of tissue damage.
Conclusion: The novel acoustic coupling fluid intended for brain tumor surgery appears safe in rats and pigs under
the tested circumstances.
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For glial brain tumors the extent of resection is associated
with survival [1,2]. However, extensive resection should
not jeopardize function [3,4]. Tools for enhancing surgical
resection of brain tumors, in particular gliomas, are in-
creasing [4-7]. Ultrasound is currently used as a tool for
providing 2D or 3D images for the purpose of tumor
localization and resection control. Ultrasound has the po-
tential to guide resections and increase resection grades,
and thereby increase survival [8]. While ultrasound image
quality is linked to resection grades in glioma surgery the
image quality may sometimes be threatened by artifacts
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unless otherwise stated.reducing the specificity [10,11]. When ultrasound is used
for resection control the resection cavity is filled with sa-
line to provide acoustic coupling between the ultrasound
transducer and tissue. However, attenuation of acoustic
waves is very low in saline compared to the brain and this
difference in attenuation may cause artifacts that degrade
the ultrasound images. Such artifacts are seen as high-
intensity signals at the resection cavity wall and beyond,
potentially masking a small tumor remnant, or even
mimic tumor when there is none, and generally make the
image interpretation more difficult (Figure 1).
This research group has developed a patent pending
fluid intended for use in the resection cavity instead of sa-
line. The effect on image quality has been tested in labora-
tory measurements using phantoms and fresh animal
cadavers. The fluid seems to enhance ultrasound imagetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Ultrasound imaging during glioma resection. Screen dump from the ultrasound based neuronavigation system (SonoWand®).
Images to the left are preoperative MRI demonstrating a hyperintense region suspect of diffuse glioma (above; sagittal view, below; coronal view).
Images in the middle represent the corresponding ultrasound images taken intraoperatively before resection. Pictures to the right demonstrate
corresponding ultrasound images approximately midway in the resection. Notice the bright-rim in the bottom of the cavity, representing an
artifact, making the interpretation of hyperintense areas that could represent tumor on the images somewhat more difficult.
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resection cavity. We believe that the acoustic fluid will
make image interpretation easier towards the end of
surgery by easing delineation of normal brain tissue and
tumor tissue, thus improving resection grades and im-
proving safety.
In this two-step animal safety study we aimed to
examine if the newly developed acoustic coupling fluid
has any harmful effect related to its intended use.Materials and methods
Study design
We designed a two-phased animal study with assessment
in eight rats first, and if no adverse reactions were de-
tected, pigs were to be included. Animals were succes-
sively included and no animals were excluded after the
initiation of the experiments. The rat experiment was a
non-randomized experimental study with each rat being
its own control as the acoustic fluid was injected in one
hemisphere and isotonic saline in the other. The pig ex-
periment included six animals in a non-randomized con-
secutive study with no controls.Experimental acoustic fluid
The (developed) acoustic coupling fluid is based on sub-
stances available in the pharmacy for intended use by
humans. In the developed fluid we tested a pharmaceutical
grade triglyceride and a pharmaceutically acceptable emul-
sifier and a pharmaceutically acceptable humectant. The
main ingredient of the fluid we use is purified soybean oil
in addition to lecithin and glycerol. These “active ingredi-
ents” is then diluted with a crystalloid solution (e.g. physio-
logic saline or Ringer’s lactate), the more you dilute the
lower the attenuation will be. From attenuation measure-
ments in the laboratory and ultrasound imaging on fresh
animal cadavers we established a certain blend of the above
mentioned ingredients that should attenuate sound waves
similarly as the human brain. See also Selbekk et al. [12].
Experimental animals
In the first phase of the study, acoustic fluid was injected
in the frontal cortex of one randomly chosen hemisphere
and control fluid in the contralateral hemisphere of eight
adult female Sprague-Dawley rats (Taconic, Denmark). In
the second phase, acoustic fluid was injected in the cis-
terna magna of six female domestic farm pigs, Sus scrofa
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was four days for three pigs and five days for the other
three pigs. One additional pig served as control for the
model of assessing epileptogenicity by injecting penicillin
G instead of the acoustic fluid into the cerebrospinal fluid
in cisterna magna. Rats were housed in groups of three
per cage in an animal facility and pigs were housed to-
gether except for the first day after the intervention when
they were kept separated. Illumination was controlled on a
12:12-h light-dark cycle at room temperature 21°C and
humidity 60% ± 2 SD. Animals had free access to water
and a pellet rodent or pig diet.
Injection of fluid in brain parenchyma of rats
The rats were anesthetized with a gas mixture of 5% iso-
flurane (Abbot Scandinavia, Solna, Sweden), O2 0.25 L ·
min-1 and N2O 0.55 L · min
-1. After induction of anesthesia
all rats received 0.012 mg atropine subcutaneous injection
diluted in 1 mL NaCl 0.9% solution. The isoflurane con-
centration was adjusted down gradually to 1.8%, not faster
than 0.5% each minute. The rat’s head was fixed in hori-
zontal position by a stereotactic frame. The procedure was
done under sterile conditions, and an operating micro-
scope was used during the surgical intervention. After ex-
posing of the cranial vault, xylocain 10% was sprayed onto
the surface and two 1 mm wide holes were drilled. Dura
mater was carefully removed using a dura hook. The fluids
were injected into the frontal lobe cortex of both hemi-
spheres at 0.16 μL · min-1 by means of a 33 gauge internal
cannula (C315I; Plastics One) inside a 26 gauge outer can-
nula (C315G; Plastics One) with the tip of the inner can-
nula protruding 0.9 mm out of the outer cannula. The
cannula was connected by polyethylene tubing to a 25 μL
Hamilton syringe in a CMA/100 microinfusion pump
(Carnegie Medicine, Stockholm, Sweden). The entry point
was 1.5 mm posterior to Bregma, 3.4 mm to both sides of
the sagital suture, and 1.5 mm deep into the somatosen-
sory cortex. A total volume of 1.00 μL fluid (either saline
or acoustic fluid) was injected, and the cannula was
retracted five minutes after each injection to prevent back-
flow of the fluid. The skin was sutured before the rats
returned to their cages. Core temperature was maintained
during the procedure using a heating pad and monitored
using a rectally inserted thermometer. The equipment and
procedure for injection were the same as used by Hafting
et al. [13].
Subarachnoid injection of fluid in cisterna magna of pigs
The pigs were sedated with a combination of 10 mL aza-
perone (40 mg · mL-1) and 2 mL diazepam (5 mg · mL-1).
Intravenous access was established via an ear vein. Just be-
fore intubation 1 mL atropin (1 mg · mL-1), 5 mL ketamin
(50 mg · mL-1), 5 mL fentanyl (50 μg · mL-1) and 5 mL
thiopentothal (25 mg · mL-1) were administered. Afterintubation the pigs remained anesthetized with 1–3% iso-
flurane (Abbot Scandinavia, Solna, Sweden), adjusted indi-
vidually, 50% oxygen with the remaining being medical air
3 L · min-1 (AGA AS, Linde Healthcare, Norway). Pigs
were positioned in prone position on a heating blanket
with the neck flexed over the operating table to facilitate
puncture of cisterna magna. Fluoroscopy was utilized for
guidance in all animals. After verification of needle pos-
ition in cisterna magna a total amount of 2 mL cerebro-
spinal fluid was collected. This equals 10% of the total
CSF volume in pigs which is approximately 20 mL [14].
With the needle in place, 1 mL of the acoustic fluid was
slowly injected and flushed with 1 mL of autologous cere-
brospinal fluid. After the injection all animals were ob-
served for 20 minutes while monitoring oxygen saturation
and heart rate with 3-lead ECG continuously. After the
observation period isoflurane was stopped. The pigs were
extubated when they were capable of unassisted breathing
and protection of airway.
Electroencephalography recordings in pigs
Scalp electroencephalography (EEG) was recorded
throughout the procedure in all pigs. The EEG protocol we
utilized equals the EEG protocol in use for children at St.
Olavs Hospital. A Schwarzer ED 21 (Picker International
GmbH) was used to record 12 channel EEG (longitudinal
bipolar, 10-20 electrode system, two common central scalp
reference electrodes were applied, the filter was 0.5–70 Hz,
sensitivity 100 mV · cm-1) which was digitized (Rhythm
version 9, Stellate Systems) using a sampling rate equal to
200 · s-1 for eight minutes. Electrode placements were: Fp1-
T3, T3-O1, Fp2-T4, T4-O2, Fp1-C3, C3-O1, Fp2-C4, C4-
O2, T3-C3, C3-Cz, Cz-C4 and C4-T4. Subcutaneously nee-
dle electrodes were used. EEG was recorded throughout
the injection procedure in all pigs. One pig served as con-
trol with the purpose to validate the model. In this pig
1 mL penicillin G (1 000 000 U · mL-1, diluted in 0.9%
NaCl) was injected at two time points with 20 minutes
interval. After the first injection the pig developed
tachycardia and generalized rhythmic fast sharp activity
(Figure 2). After the second injection there was after
three minutes markedly pathological EEG (generalized
spikes, spike/wave and slow waves) consistent with on-
going seizure activity (Figure 3). After additional seven
minutes the pig developed frequent widespread and
small muscle contractions, and the pig was then eutha-
nized according to protocol with an overdose of 10%
pentobarbital.
Follow-up and assessment of animals
In rats, weight was measured prior to, right after, and nine
days after the procedure. All animals, rats and pigs, had
supervision at least two times daily and any abnormal be-
havior and signs of CNS affection after the procedure was
Figure 2 EEG registrations immediate after the first injection of penicillin G leading to generalized rhythmic fast sharp activity.
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behavior, the level of stress and activity and animal appear-
ance like body posture and fur (bristling or not) were reg-
istered. Behavior in pigs was systematically scored twice
daily to enable capturing of any abnormal behavior or
negative trends (Table 1).
Brain biopsy of rats
The whole brain was acquired the ninth day after the sur-
gical procedure. Isoflurane (Abbot Scandinavia, Solna,Figure 3 EEG registrations after the second injection of penicillin G leSweden) was used to induce anesthesia, followed by in-
traperitoneal injection of an overdose of 10% pentobar-
bital (300 mg · kg-1). When the rats stopped breathing, the
thorax was immediately opened and 100 mL phosphate-
buffered saline was injected through the left cardiac ven-
tricle while the heart was still beating, followed by 100 mL
injection of 4% formalin for intravascular fixation of the
brain parenchyma, a method adapted from Wideroe et al.
[15]. Injection rate was set to 35 mL · min-1. An incision in
the right atrium allowed solution to leave the circulation,ading to seizure activity.
Table 1 Scores of symptoms in pigs post-procedure
Day 2 Day 4 Day 6 Day 8 Day 10 Day 12
Pig 1 0/12 0/12 1/12 1/12 1/12 1/12
Pig 2 0/12 1/12 0/12 0/12 0/12 0/12
Pig 3 0/12 0/12 0/12 0/12 0/12 0/12
Pig 4 1/12 2/12 0/12 0/12 0/12 0/12
Pig 5 0/12 0/12 0/12 0/12 0/12 0/12
Pig 6 2/12 2/12 1/12 0/12 0/12 0/12
The score was predefined by a veterinarian and the score was based on:
appearance, behavior, nutritional status and relevant clinical signs (gait
disturbances and/or seizure). For each dimension a range from 0 (normal) to 3
(markedly abnormal) was possible giving a range from 0-12 on each observation.
The scores presented were from the assessment where the individual pig reached
the highest sum (most symptoms). A total score of 0-3 was predefined as normal
unless the pig scored 3 in one dimension (severe symptoms). A total score higher
than 3 or maximal score in one dimension warranted a consult with
a veterinarian.
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damage. The head was then decapitated and embedded in
4% buffered formalin for two weeks prior to histopatho-
logical analysis.
Brain biopsy of pigs
The brain biopsies were acquired at day 13 for three pigs
and at day 16 for the other three. The pigs were sedated
with 2 mL stesolid (5 mg · mL-1), 4 mL azaperone
(40 mg · mL-1), 14 mL ketamin (50 mg · mL-1) and later
euthanized with 40 mL 10% pentobarbital. Shortly after
injection a large craniectomy was performed. Sampling
of dura and brain parenchyma both above and below the
tentorium was performed and acquired biopsies were
embedded in 4% buffered formalin. In addition, plexus
choroideus were sampled in all pigs.
Assessment of histopathology
In the rat experiment the brain was cut in coronal sec-
tions (2 mm) and embedded in paraffin. From the
paraffin-blocks 4 μm thick sections were cut, stained
with haematoxylin-eosin, and examined microscopically.
To assess processes such as gliosis, fibrosis or inflamma-
tion immunohistochemistry was performed using anti-
bodies against lymphocytes (CD3 for T-cells and CD20 for
B-cells), microglia/macrophages (CD68), and reactive as-
trocytes (glial fibrillary acidic protein (GFAP)).
Tissue samples of pig brain from supratentorial, infra-
tentorial and brain stem region were fixed in buffered 4%
formalin and embedded in paraffin. Paraffin-sections of 4
μm thickness were cut, stained with haematoxylin-eosin
for microscopical analyses. The sections were also incu-
bated with antibodies against GFAP, CD45 (leukocyte
common antigen), and CD68 (microglial activation). The
immunostaining was carried out on a DAKO Autostainer
(Dako, Glostrup, Denmark). Visualization of immunoreac-
tivity was performed with DAKO EnVision system withdiaminobenzidin as chromogene. Sections were counter-
stained with haematoxylin. Positive controls were included
in each staining run. In the negative controls the primary
antibodies were omitted.
The neuropathologist (SHT) was blinded with respect to
all data concerning the animal status and which side it
was saline or acoustic fluid injection in the rat experiment.
Statistical considerations
As the primary end-points were qualitative in nature
(animal behavior, EEG registrations, histopathology and
immunohistochemistry) we only present descriptive ana-
lysis. Average is presented as mean ± standard deviation.
Ethical approval
The experimental protocols were reviewed and approved
by the Norwegian Committee for Animal Experiments,
and conform to the European Convention for the Pro-
tection of Vertebrate Animals Used for Experimental
and other Scientific Purposes.
Results
General
The mean weight of the eight rats was 273 g ± 8 before
the procedure and 267 g ± 8 after nine days post-
procedure. The mean weight of the six pigs was 37 kg ± 2
before the procedure and 43 kg ± 4 at end of follow-up.
Animal behavior
In rats, no apparent discomfort or altered behavior was reg-
istered during the follow up assessment. In pigs the post-
procedure behavior was scored systematically (Table 1)
without detection of adverse events (score ≥ 3/12).
EEG registrations
In the six animals receiving injection of the acoustic
fluid we have five EEG registrations with good quality.
Median registration time was 43 minutes (range 26 –
54 minutes) with all pigs having more than 20 minutes
of registration post-injection. For unknown reasons
one EEG recording disappeared at attempt of storing.
This pig (pig 5) did not appear any different with re-
spect to heart rate, oxygen saturation or behavior after
the procedure. The pig had an uneventful immediate
recovery. In the other five pigs there were EEG record-
ings of good quality and there were no signs of seizure
activity. Figure 4 demonstrates the pre- and post-
procedure EEG in pig 3.
Histopathological assessment
No inflammation or tissue damage was seen after injection
of the acoustic or control fluid in rat brain parenchyma
with any of the techniques used. Figure 5 demonstrates
the area of injection without any reactions. In pigs
Figure 4 EEG registrations in pig 3. a) Before the procedure. Synchronous background activity 4-6 Hz with highest amplitudes in the
frontotemporal region. b) After injection of the acoustic coupling fluid. There was no evidence of seizure activity on EEG.
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mation, neither in meninges, nor in brain tissue or vessels.
Furthermore, no gliosis or microglial response was ob-
served after immunohistochemistry. In the brain-stem
biopsy in pig 4 a small focal area was observed with afew lymphocytes, eosinophiles, macrophages and slight
spongiforme changes (subtle loss of neural tissue). No
neutrophile granulocytes were observed. This focal area
appeared microscopically to be of a chronic character
and not due to the procedure.
Figure 5 Histology of injection site of the acoustic fluid in rat. There was a minor macrophage response just around the needle site which is
a normal reaction to brain trauma. Except from this there was no evidence of any reactions around the needle site.
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In this safety study in rats and pigs we were unable to
detect adverse clinical events of the newly developed
acoustic coupling fluid for improving image quality in
ultrasound-guided operations. Intra-procedure EEG was
also unable to demonstrate any signs of epileptogenic ef-
fects. Also, there were no signs of acute inflammation in
histopathological samples.
The intention with this testing was a relevant and so-
phisticated administration of the acoustic fluid (intra-
parenchymal and subarachnoidal) in two different species.
Thus, we examined a local effect in rats and a more re-
gional effect in pigs. The administration methods were
chosen to minimize procedural damage, thereby enhan-
cing post-procedural observation. The refined assessment
was important to be able to detect any subtle damage to
nervous tissue or its surroundings. Also, such methods are
also in line with the 3R’s (refinement, reduction, replace-
ment) in animal research.
Although no adverse events or signs of toxicity were ob-
served in the two animal models, toxicity may be both
dose-dependent and time-dependent. In rats 1 μL was
injected intraparenchymal (approximately 1/2000 of the
mean brain volume) and in pigs 1 mL was administered
into the subarachnoid space (approximately 5% of total
CSF volume) [14]. This would equal accumulation of
7.5 mL in the human CSF. Since the acoustic coupling
fluid is likely to be opaque, a prerequisite for the useful-
ness would be 3D ultrasound imaging so that the region
of interest in the ultrasound image can be retrieved. With
ultrasound it is possible to update the image information
several times during a brain tumor resection to follow theprogression of tumor resection and to correct for brain
shift [6]. Thus, repeated administration and removal of the
acoustic fluid will be carried out. Acquisition of a 3D
ultrasound image recording typically takes 2-3 minutes.
Thereafter the coupling fluid will be removed with suction
and irrigation. Topical accumulation of the fluid is un-
likely since the surgeons after image acquisition would
want to remove the fluid since it is opaque. Also, most of
the fluid will presumably stay in the resection cavity since
a horizontal craniotomy is most often attempted when
brain tumor resections are facilitated by ultrasound [6].
The experience in animals is that the fluid is easily re-
moved by suction and flushing with Ringer’s solution. A
potential pitfall for excessive accumulation of the fluid to
levels higher than tested in the animals could be in tumors
where the ventricles are opened as a result of tumor resec-
tion. This could be the case in tumors similar to the situ-
ation seen in Figure 1. In these situations special care is
necessary and until further safety data is available our re-
commendation is that fluid should not be administered
after opening the ventricles.
The strengths of the model are testing of both rats and
pigs in addition to use of relevant application methods
(intraparenchymal and subarachnoid space) with sophisti-
cated methods and the use of EEG monitoring. However,
the drugs used to sedate the pigs could possibly increase
the seizure threshold and mask EEG disturbances. Also,
due to the number of tested animals it remains a possibi-
lity that more rare events may have gone unnoticed. How-
ever, further animal testing for rare events or reactions
due to very high doses or delayed effects was considered
less relevant because of the benign profile seen in our
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or negative toxicity findings from animal to humans are
naturally always subject to uncertainty due to the inherent
biological differences. We decided that the potential gain of
further animal testing was limited and consequently we de-
signed a study assessing safety in selected brain tumor
patients. Recently this protocol was approved by the
Norwegian Medicines Agency and the local ethical com-
mittee and we are now in the beginning of a phase 1 safety
study (EudraCT number 2012-005567-27).
The acoustic fluid holds potential to enhance image
quality when using 3D ultrasound in brain tumor resec-
tions. We hope this will make image interpretation easier
at the end of a brain tumor resection, an improvement that
could be of particular importance for users with limited ex-
perience in using ultrasound guided surgery. Improved im-
aging near the end of the surgery could be associated with
improved resection grades that again improves clinical out-
come [2,4,5,16]. We now hope to translate these positive
findings from simulation and the animal models to highly
selected patients with suspected high-grade glioma to fur-
ther evaluate the potential benefits while carefully monitor
any potential adverse events.
Conclusion
We have in rats and pigs demonstrated that the newly de-
veloped acoustic coupling fluid intended for use in
ultrasound-guided brain tumor surgery appears safe under
the tested circumstances. We are now in the beginning of
a phase 1 clinical study where different concentrations of
the acoustic coupling fluid is tested in selected patients at
our institution in order to assess safety and impact on
ultrasound image quality.
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